| Literature DB >> 25140138 |
Thomas P White1, Rebekah L Wigton1, Dan W Joyce1, Tracy Bobin1, Christian Ferragamo1, Nisha Wasim1, Stephen Lisk1, Sukhwinder S Shergill1.
Abstract
Perceptions are inherently probabilistic; and can be potentially manipulated to induce illusory experience by the presentation of ambiguous or improbable evidence under selective (spatio-temporal) constraints. Accordingly, perception of the McGurk effect, by which individuals misperceive specific incongruent visual and auditory vocal cues, rests upon effective probabilistic inference. Here, we report findings from a behavioral investigation of illusory perception and related metacognitive evaluation during audiovisual integration, conducted in individuals with schizophrenia (n = 30) and control subjects (n = 24) matched in terms of age, sex, handedness and parental occupation. Controls additionally performed the task after an oral dose of amisulpride (400 mg). Individuals with schizophrenia were observed to exhibit illusory perception less frequently than controls, despite non-significant differences in perceptual performance during control conditions. Furthermore, older individuals with schizophrenia exhibited reduced rates of illusory perception. Subsequent analysis revealed a robust inverse relationship between illness chronicity and the illusory perception rate in this group. Controls demonstrated non-significant modulation of perception by amisulpride; amisulpride was, however, found to elicit increases in subjective confidence in perceptual performance. Overall, these findings are consistent with the idea that impairments in probabilistic inference are exhibited in schizophrenia and exacerbated by illness chronicity. The latter suggests that associated processes are a potentially worthwhile target for therapeutic intervention.Entities:
Keywords: McGurk effect; dopamine; multisensory integration; probabilistic inference; schizophrenia
Year: 2014 PMID: 25140138 PMCID: PMC4122162 DOI: 10.3389/fnhum.2014.00565
Source DB: PubMed Journal: Front Hum Neurosci ISSN: 1662-5161 Impact factor: 3.169
Sample details.
| Age (years) | 39.03 (8.60) | 36.67 (8.97) | |
| Range: 25–54 | Range: 22–50 | ||
| Sex (male/female) | 27/3 | 21/3 | χ2 (1, |
| Parental occupation (NS-SEC) | 3.10 (1.70) | 2.50 (1.67) | |
| Intelligence quotient (WASI) | 95.62 (13.68) | 108.21 (15.80) | |
| Chlorpromazine equivalent doses (mg/day) | 463.25 (330.62) | ||
| Range: 133–1100 | |||
| Positive | 14.32 (4.83) | ||
| Negative | 18.96 (5.90) | ||
| General | 30.59 (7.09) | ||
NS-SEC, National Statistics Socio-economic Classification (Rose and Pevalin, 2001); WASI, Wechsler Abbreviated Scale of Intelligence (Wechsler, 1999); PANSS, Positive and negative syndrome scale for schizophrenia (Kay et al., 1987).
Figure 1Group-averaged perceptual performance for the three condition types, for the schizophrenia group (left), and the healthy group after placebo (center) and after amisulpride (right). Error bars signify standard errors of the means. McG, McGurk trials; Inc, incongruent non-McGurk trials, Cont, control congruent trials.
Figure 2The relationship between illusory perception and age, showing .
Effects of group and age on the McGurk.
| McGurk | Group | likelihood ratio χ2 = 4.91, |
| Age | likelihood ratio χ2 = 4.55, | |
| Group-by-age | likelihood ratio χ2 = 6.44, | |
| McGurk | Group | likelihood ratio χ2 = 3.43, |
| Age | likelihood ratio χ2 = 0.41, | |
| Group-by-Age | likelihood ratio χ2 = 3.85, | |
| McGurk | Group | likelihood ratio χ2 = 3.67, |
| Age | likelihood ratio χ2 = 0.06, | |
| Group-by-Age | likelihood ratio χ2 = 3.81, |
Figure 3Group-averaged McGurk. Blue bars show McGurk rates, white bars show McGurk rates. Error bars signify the standard errors of the mean.
Figure 4The relationship between McGurk non-illusory perception and age, showing .
Confidence ratings categorized by experimental condition and group.
| McGurk | Overall | 6.91 ± 1.96 (29) | 7.03 ± 1.78 (24) | 7.55 ± 1.63 (20)* |
| Optimal response | 6.56 ± 2.29 (25) | 6.06 ± 1.93 (24) | 6.84 ± 2.08 (17) | |
| Other response | 7.01 ± 2.01 (29) | 7.14 ± 1.77 (23) | 7.83 ± 1.62 (19) | |
| Incongruent | Overall | 8.15 ± 1.47 (29) | 8.84 ± 0.93 (24) | 8.89 ± 0.89 (20) |
| Optimal response | 8.21 ± 1.44 (29) | 8.86 ± 0.93 (24) | 8.89 ± 0.90 (20) | |
| Other response | 4.84 ± 2.38 (14) | 6.28 ± 4.94 (3) | 5.30 ± 4.71 (3) | |
| Control | Overall | 8.19 ± 1.44 (29) | 8.78 ± 0.93 (24) | 8.88 ± 0.88 (20) |
| Optimal Response | 8.22 ± 1.44 (29) | 8.79 ± 0.93 (24) | 8.90 ± 0.88 (20) | |
| Other response | 7.41 ± 2.16 (22) | 7.05 ± 3.22 (10) | 6.44 ± 2.84 (5) | |
Group-averaged mean value ± standard deviations. Bracketed values denote number of individuals contributing to mean value. Asterisks denote significant differences between drug conditions in healthy individuals as assessed via paired-samples t-tests. Independent samples t-tests revealed no significant between-group differences in confidence.